Page 33 - CIBERES2016-ENG

Most relevant scientific articles
• Agusti A. Simple versus complex COPD: Implications for health-care management. The Lancet Respiratory Medicine. 2016;4(2):e6-e7.
• Faner R., Cruz T., Casserras T., Lopez-Giraldo A., Noell G., Coca I. et al. Network analysis of lung transcriptomics reveals a distinct b-cell signature in emphysema. American Journal of Respiratory and Critical Care Medicine. 2016;193(11):1242-1253.
• Singh D., Roche N., Halpin D., Agusti A., Wedzicha J.A., Martinez F. J Current controversies in the pharmacological treatment of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine. 2016;194(5):541-549.
• Agusti A., Bel E., Thomas M., Vogelmeier C., Brusselle G., Holgate S. et al. Treatable traits: Toward precision medicine of chronic airway diseases. European Respiratory Journal. 2016;47(2):410-419.
• Cosio B.G., Shafiek H., Iglesias A., Yanez A., Cordova R., Palou A. et al. Oral Low-dose Theophylline on Top of Inhaled Fluticasone-Salmeterol Does Not Reduce Exacerbations in Patients With Severe COPD: A Pilot Clinical Trial. Chest. 2016;150(1):123-130.
Highlights
During this year, the principal investigator of the group (Dr. Alvar Agusti) has been designated as the chair of the GOLD (Global Initiative for Chronic Obstructive Lung Disease), entity designated to generate global consensus for the diagnosis, treatment and prevention of COPD.
Dr. Borja Cosío has been included in the Scientific Committee of the Spanish COPD guideline, participating in the actualization that will be released in 2017. Furthermore, a non-commercial clinical study promoted from this Ciberes group, with the participation of several groups, has clarified the role of Theophylline in severe COPD patients, these observations have been included in the new Gold guideline.
Rosa Faner, member of the group, this year has been awarded with a Miguel Servet I grant, and the young investigator grant in COPD from AstraZeneca.
The group has been involved with other CIBERES groups in the organization of the international symposium “The Microbiome in Respiratory Medicine”.
RES
research groups 33